NeuroSense Therapeutics Ltd (NRSN)

[frankyahoo]

Ty. Good to see you too. Let's make bank
$NRSN

[subslover]

Hi franky, great to see you! Yea this babe just got a pin in her ass! Screaming higher!

[frankyahoo]

Wow! Finally moving. I mean ALS...Come on man! It's major good news
$NRSN

[subslover]

Yup and now starting to get more investor interest

[frankyahoo]

Cool. Seeing a small spike premarket. $NRSN

[subslover]

NeuroSense Therapeutics reports completion of the "in-life" phase of its 90-day GLP Toxicology study successfully. All animals appeared normal, with no significant findings observed. In this study the components of PrimeC, celecoxib and ciprofloxacin, were administered to rodents at doses 4x the maximal clinical dose. The company will present the data obtained in this study to the FDA as part of PrimeC's drug development plan.

[frankyahoo]

$NRSN

[subslover]

Exactly! Nice to meet you!

[swampboots]

NRSN 2.42- why drop from 3.30 spike?

[$treet $inatra]

Great spike up today! Protect profits... especially in this market..

[subslover]

NeuroSense Therapeutics Reports Positive Results from Stage III ALS Biomarker Study
Preliminary results show levels of disease-related biomarkers remain unchanged in people living with ALS who are treated with standard of care, in contrast to the statistically significant decline in these biomarkers in patients treated in NeuroSense's Phase IIa study with PrimeC
New biomarker data in people with ALS validates NeuroSense's clinical strategy
CAMBRIDGE, Mass., June 27, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced results from Stage III of its biomarker study conducted in collaboration with Massachusetts General Hospital (MGH) to evaluate PrimeC, NeuroSense's lead combination drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). PrimeC is currently being evaluated in NeuroSense's Phase IIb PARADIGM study following the successful conclusion of its Phase IIa study which met its primary endpoints.


The purpose of the initial ALS biomarker study (Stage I) was to characterize the baseline phenomena observed in people living with ALS. The study identified novel ALS biomarkers that are indicative of PrimeC's mechanism of action (MOA), via an analysis comparing blood samples obtained from healthy people and from people living with ALS. TDP-43 accumulation and neuroinflammation via prostagladin2 were amongst the disease-modifying targets characterized, along with miRNA dysregulation, iron accumulation, lysosomal dysfunction, and impaired autophagy.

Stage II investigated the therapeutic effect of PrimeC. In NeuroSense's Phase IIa study, blood samples were analyzed to determine the longitudinal effect of PrimeC on the biomarkers identified in Stage I. Following 12 months of administration with PrimeC, statistically significant changes in key ALS-related biomarkers were observed in study participants. Furthermore, the study established a correlation between the clinically meaningful outcomes detected and modulations in those biomarkers.

The Stage III natural history study analyzed blood samples from people living with ALS, treated with standard of care. Preliminary results show that levels of disease-related biomarkers remain steady and unchanged in people living with ALS, in contrast to the statistically significant decline portrayed in these biomarkers when PrimeC was administered in addition to the standard of care. Stage III results further confirmed PrimeC's MOA, and expanded insight into ALS-related biomarkers and their correlation to the progression of ALS symptoms.

"These results are very encouraging, especially in that they validate NeuroSense's clinical strategy. The biomarker study, along with the data we collect from our Phase IIb study, will inform the optimization of a pivotal Phase III study of PrimeC in ALS," stated NeuroSense's CEO, Alon Ben-Noon. "NeuroSense is honored to collaborate with the world-class MGH team on this critical study."

"NeuroSense remains at the forefront of biomarker research with the inclusion of a comprehensive portfolio of biomarkers in our Phase IIb study. This is essential in exploring mechanistic associations in ALS," stated Dr. Shiran Zimri, Head of Scientific Programs at NeuroSense. "The use of neuronal derived exosomes (NDE), a cutting-edge technology, allows one to observe key alterations in biomarkers found in the central nervous system. We look forward to sharing more detailed results at the upcoming World Orphan Drug Congress in Boston, Massachusetts on July 11-13th."

About PrimeC

PrimeC, NeuroSense's lead drug candidate is a combination therapy that was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). NeuroSense completed a Phase IIa clinical study which successfully met its safety and efficacy endpoints including reducing functional and respiratory deterioration and statistically significant changes in ALS-related biological markers indicating PrimeC's biological activity. Through a collaboration with Massachusetts General Hospital in Boston on novel Neuron-Derived Exosomes (NDEs), NeuroSense is working to further analyze the results and correlations to the clinical data, to determine the biological changes in ALS-related pathologies and the magnitude of the effect of PrimeC on relevant targets.

About ALS

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 patients are diagnosed with ALS in the U.S. alone, with an

[$treet $inatra]

$NRSN due for a run with the bouncing market

https://stockcharts.com/c-sc/sc?s=NRSN&p=W&yr=1&mn=10&dy=0&i=t7504703061c&r=1655494070699

https://clinicaltrials.gov/ct2/show/NCT05357950

NASDAQ 2M nano-float, 11M O/S

ALS study updates to come https://finance.yahoo.com/news/neurosense-enrolls-first-patient-phase-123000179.html

https://www.neurosense-tx.com

[heyitsmeagain]

Added more

[heyitsmeagain]

Dunno what is but bought 25000 shares

[420man]

Do what?.. It was down 30% yesterday morning. Easy comeback from you once it recovered. Try not to be a dick. I'd say she drops hard over the next few weeks.

[THEMASTERS_SON]

,,,,,,,MAKE SURE U FOLLOW ME


I’M FINISHING THIS THING LIKE WE STARTED.


TALENT ON LOAN FROM…..GOD


SEE YOU AT $5

[THEMASTERS_SON]

,,,,,,,BACK IN THIS ONE TOMORROW

[HeilHiden]

Momentum sma is above the ceiling!

[HeilHiden]

Shares are thin up to 7.5!

[HeilHiden]

Lock and load them!

[HeilHiden]

Large MM buys 5.50+ I am very confident we will see higher than that.

[Sibware]

NRSN: Let's break that $8

[THEMASTERS_SON]

,,,,,,,,WRONG

[THEMASTERS_SON]

,,,,,,,BOOM! $6.30’s…TALENT ON LOAN FROM….GOD!

[THEMASTERS_SON]

WE GREEN$

[THEMASTERS_SON]

,,,,,,SQUEEEEEEEEEEZE SEND THEM TO $12|GATES..OF…HELL

[TheFinalCD]

$5 re-break!!

[THEMASTERS_SON]

5M FLOAT…..ON LOCK!! WEEEEE

[THEMASTERS_SON]

,,,,,,THANKS UP $20K BUYING DIP EOM

[THEMASTERS_SON]

LET’S GO TEN $$

[THEMASTERS_SON]

5M FLOAT = LGV*

[THEMASTERS_SON]

,,,,,,,IT’S REALLY HAPPENING CURE ALS

[TheFinalCD]

BAIT? lol

[conix]

NRSN Chart



NeuroSense surges on FDA nod to study ALS candidate in healthy subjects
Mar. 21, 2022 9:03 AM ETNeuroSense Therapeutics Ltd. (NRSN)

By: Dulan Lokuwithana, SA News Editor



Israel-based, clinical-stage biotech, NeuroSense Therapeutics (NASDAQ:NRSN) has added ~32% in the pre-market Monday after announcing that the U.S. Food and Drug Administration (FDA) greenlighted a pharmacokinetic study for its lead asset, PrimeC in healthy adult subjects.
An oral combination of FDA-approved drugs, ciprofloxacin, and celecoxib, PrimeC is designed to target amyotrophic lateral sclerosis (ALS).
With its Investigational New Drug (IND) application, NeuroSense (NRSN) has sought the FDA nod to run a pharmacokinetic study to evaluate the effects of food on the bioavailability of PrimeC as opposed to the bioavailability of co-administered ciprofloxacin and celecoxib. The Phase 1 study is set to involve 12 healthy adults in the US.
NeuroSense (NRSN) has already completed a successful Phase IIa trial for the candidate, and a Phase IIb global study is expected to start in Q2 2022.

[THEMASTERS_SON]

,,,,,,,IF LGV$& CAN GO>>$45 WHY…NOT US!!!!

[Just-Keep-Trying]

Yep!! As I noted, pure 'SUCKERS BATE' right out of the starting gate today!!

[Just-Keep-Trying]

And all because the SEC, OTC, & FBI finally have-assed 'CLEANED-UP' the OTC Cirus!

[Just-Keep-Trying]

Yep!

[Just-Keep-Trying]

But NRSN's STOCK sure got some "action" today!

[420man]

Dumpathon tomorrow. Yikes.

[TheFinalCD]

https://finance.yahoo.com/news/neurosense-shares-surge-over-400-162950959.html

[koolmc]

lol

[Sibware]

NRSN-NRSNW:Ihubbers always late...lol.IHUB will never be great again

[Sibware]

NRSN-NRSNW:Offering-was $6 & insiders usually-sell 4 easy-double fwiw

[Just-Keep-Trying]

And here's why: NRSN is a classic 'Suckers Bate' play for the REST of this day, Homeboys!!! And all behind a POTENTIAL "Lou Gehrig's Disease" treatment???!!! Are you fluckin' KIDDING me???!!! A disease that afflicts ONLY 5,000 peeps per year in the USA --- but NRSN Company is gonna SOAR in price forever now, right????? This PRICE per share ain't gonna last another 10-minutes!!! Are you feelin' LUCKY????!!!!!

[rakp]

Amazing, up 250%?

[stocks2watch]

It's being talked about on twitter.Look at Anya.She had it on her watch list today.

[koolmc]

no posts?

[saigai]

shorts aren't investors they are vandals

[saigai]

i read stockwits and people just dont get it. the stock nearly double yesterday on very high volume..retracing on low volume ..surprise surprise and the mkts are crashing again.. im not selling one share